Digital Diabetes Prevention Program Study
NCT06137963 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL
Last updated 2024-12-27
Summary
The aim of this study is to determine if completion of the Diabetes Prevention Program (DPP) via the Transform 10 website can significantly decrease hemoglobin A1c (HbA1c) levels and Body Mass Index (BMI) in prediabetic individuals undergoing total hip arthroplasty (THA) procedure.
As part of the standard procedure of the Centers for Disease Control (CDC)-approved DPP program, all study participants will report their active minutes and weight via the Transform10 website throughout the 6 month-long program. In addition, participants will have a repeat Hba1c test ordered at the end of the program by the medical director as part of routine procedures. The main questions it aims to answer are:
1. Is an augmented digital diabetes prevention program an effective strategy for weight loss in adults with prediabetes undergoing elective total hip arthroplasty?
2. Is an augmented digital diabetes prevention program an effective strategy to decrease HbA1c in adults with prediabetes undergoing elective total hip arthroplasty?
3. Is an augmented digital diabetes prevention program an effective strategy to improve postoperative outcomes and patient satisfaction in adults with prediabetes undergoing elective total hip arthroplasty?
Participants will be randomized to get the DPP on their day of surgery (intervention group) or get their DPP 6 months after their day of surgery (control group).
Comparing the intervention group to the control group, the researcher's primary outcome is change in percent of body weight before and after a 6-month intervention period.
Conditions
Interventions
- OTHER
-
Transform10 Diabetes Prevention Program
The Transform10 app includes a Centers for Disease Control (CDC)-approved diabetes prevention program. The self-paced curriculum and optional video content covers: * Strategies to overcome emotional eating using cognitive behavioral therapy principles. * Improving cardiovascular function with capacity-matched training programs using participants' estimated cardio scores. * An introductory-level course for increasing muscle and bone density foundation via strength training. * Education regarding physical therapy and expectations for patients. The Transform10 app also provides access to lifestyle coaches who discuss evidence-based information regarding hunger and insulin, macronutrient strategies, time-restricted intermittent fasting, and inflammation.
Sponsors & Collaborators
-
Hospital for Special Surgery, New York
lead OTHER
Principal Investigators
-
Jashvant Poeran, MD/PhD · Hospital for Special Surgery, Department of Anesthesiology
-
Stephanie Cheng, MD · Hospital for Special Surgery, Department of Anesthesiology
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 64 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-01-24
- Primary Completion
- 2024-04-04
- Completion
- 2024-04-04
Countries
- United States
Study Locations
More Related Trials
-
Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)
NCT02969798 ·Status: RECRUITING ·Phase: NA
-
Impact of Metabolic Surgery on Pancreatic, Renal and Cardiovascular Health in Youth With Type 2 Diabetes
NCT03620773 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
The Contribution of Incretin Hormones to Post-prandial Glucose Metabolism After Roux-en-Y Gastric Bypass
NCT01843881 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
The Endocrine Impact of the Duodenal-jejunal Bypass Sleeve on Type 2 Diabetes - Potential Role of the Incretin Hormones
NCT02360878 ·Status: COMPLETED
-
The Effect of GIP, GLP-1 and GLP-2 in Individuals With Genetically Altered Receptor Function
NCT06194955 ·Status: COMPLETED ·Phase: NA
-
The Separate and Combined Effects of Long-term GIP and GLP-1 Receptor Activation in Patients with Type 2 Diabetes
NCT05078255 ·Status: COMPLETED ·Phase: NA
-
The Importance of GLP-1 in Post RYGB Improvement in Glycaemic Control Type 2 Diabetic Subjects
NCT01579981 ·Status: COMPLETED ·Phase: NA
-
The Effect of Gastric Bypass Surgery on the Glucose Metabolism Seen in Patients With Type 2 Diabetes
NCT00810823 ·Status: COMPLETED
-
Effect of GLP-1 on Insulin Biosynthesis and Turnover Rates
NCT00609154 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
DSS: Diabetes Surgery Study - Intensive Medical Management of Type 2 Diabetes, With and Without Gastric Bypass Surgery
NCT00641251 ·Status: COMPLETED ·Phase: NA
-
Effect of GLP-1 Receptor Agonists on Trabecular Bone Score
NCT04964388 ·Status: TERMINATED ·Phase: PHASE2
-
Study TO Prevent Diabetes With Short-term Insulin Glargine Only
NCT01276912 ·Status: UNKNOWN ·Phase: NA
-
Metabolic Phenotyping During Stress Hyperglycemia in Cardiac Surgery Patients
NCT03743025 ·Status: TERMINATED ·Phase: PHASE4
-
Duodenal Exclusion for the Treatment of Type 2 Diabetes
NCT00534547 ·Status: WITHDRAWN ·Phase: NA
-
Efficacy of Glucagon In the Prevention of Hypoglycemia During Mild Exercise
NCT03217175 ·Status: TERMINATED ·Phase: NA
-
To Define the Role of GLP-1 for Improving Glucose Homeostasis in Humans Following Gastric Bypass Surgery
NCT02204813 ·Status: COMPLETED ·Phase: PHASE1
-
Semaglutide for the Treatment of Glucose Intolerance in Women With Prior Gestational Diabetes
NCT05569772 ·Status: RECRUITING ·Phase: PHASE3
-
Influence of Glucagon Inhibition in Relation to the Anti-Diabetic Effect of Glucagon-Like Peptide-1 (GLP-1) in Patients With Type 2 Diabetes Mellitus
NCT00655603 ·Status: UNKNOWN ·Phase: NA
-
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
NCT01803451 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
A Study of LY3457263 Alone and in Combination With Dulaglutide (LY2189265) in Participants With Type 2 Diabetes
NCT05377333 ·Status: COMPLETED ·Phase: PHASE1
-
Treatment of GLP-1 for Diabetic Bariatric Patients
NCT04624672 ·Status: TERMINATED ·Phase: PHASE4
-
Collection of Human Liver Biopsy and Whole Blood Samples From T1DM, TP or PP Patients for Potential Use for Insulin Producing Cells in Future Clinical Studies
NCT04038931 ·Status: UNKNOWN
-
Central Mechanisms That Regulate Glucose Metabolism in Humans
NCT01028846 ·Status: TERMINATED ·Phase: PHASE4
-
GLP-1Ra Impact on Metabolic Outcomes in Stage 2 T1DM While Receiving Teplizumab
NCT06338553 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Metabolic Effects of Duodenal Jejunal Bypass Liner for Type 2 Diabetes Mellitus
NCT02800668 ·Status: COMPLETED